Farglitazar

Farglitazar
Clinical data
Pregnancy; category	N/A;
ATC code	none;
Legal status
Legal status	Development discontinued;
Identifiers
	IUPAC name N-(o-Benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine;
CAS Number	196808-45-4 ;
PubChem CID	170364;
IUPHAR/BPS	2672;
ChemSpider	148961 ;
UNII	3433GY7132;
KEGG	D04132;
ChEMBL	ChEMBL107367 ;
CompTox Dashboard (EPA)	DTXSID1047310 ;
Chemical and physical data
Formula	C34H30N2O5
Molar mass	546.623 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5;
	InChI InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 ; Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N ;
	(what is this?) (verify)

Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy.^[1] After reaching phase III for type 2 diabetes, further development was discontinued.^[2]^[3]

References

^ McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, et al. (April 2010). "Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection". Gastroenterology. 138 (4): 1365–73, 1373.e1-2. doi:10.1053/j.gastro.2009.12.003. PMID 20004661.
^ "Farglitazar". Adis Insight. Springer Nature Switzerland AG.
^ "Farglitazar". pharmacodia.com.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[1] McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, et al. (April 2010). "Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection". Gastroenterology. 138 (4): 1365–73, 1373.e1-2. doi:10.1053/j.gastro.2009.12.003. PMID 20004661.

[2] "Farglitazar". Adis Insight. Springer Nature Switzerland AG.

[3] "Farglitazar". pharmacodia.com.

[1]

[2]

[3]

v t e PPARTooltip Peroxisome proliferator-activated receptor modulators
PPARαTooltip Peroxisome proliferator-activated receptor alpha	Agonists: 15-HETE 15-HpETE Aleglitazar Aluminium clofibrate Arachidonic acid Bezafibrate Chiglitazar Clofibrate CP-775146 Daidzein DHEA (prasterone) (in rodents) Elafibranor Etomoxir Fenofibrate Genistein Gemfibrozil GW-7647 Lanifibranor Leukotriene B₄ LG-101506 LG-100754 Lobeglitazone Muraglitazar Oleylethanolamide Palmitoylethanolamide Pemafibrate Perfluorononanoic acid Perfluorooctanoic acid Pioglitazone Saroglitazar Sodelglitazar Tesaglitazar Tetradecylthioacetic acid Troglitazone WY-14643 Antagonists: GW-6471 MK-886
PPARδTooltip Peroxisome proliferator-activated receptor delta	Agonists: 15-HETE 15-HpETE Arachidonic acid Bezafibrate Daidzein Elafibranor Fonadelpar Genistein GW-0742 GW-501516 L-165,041 Lanifibranor LG-101506 Seladelpar Sodelglitazar Tetradecylthioacetic acid Antagonists: FH-535 GSK-0660 GSK-3787
PPARγTooltip Peroxisome proliferator-activated receptor gamma	Agonists: 5-Oxo-ETE 5-Oxo-15-hydroxy-ETE 15-Deoxy-Δ^12,14-prostaglandin J₂ 15-HETE 15-HpETE Aleglitazar Arachidonic acid Balaglitazone Berberine Bezafibrate Cannabidiol Cevoglitazar Chiglitazar Ciglitazone Daidzein Darglitazone Edaglitazone Efatutazone Englitazone Etalocib Farglitazar Genistein GW-1929 Ibuprofen Imiglitazar Indeglitazar Lanifibranor LG-100268 LG-100754 LG-101506 Lobeglitazone Muraglitazar (muroglitazar) nTZDpa Naveglitazar Netoglitazone Oxeglitazar Peliglitazar Pemaglitazar Perfluorononanoic acid Pioglitazone Prostaglandin J₂ Ragaglitazar Reglitazar Rivoglitazone Rosiglitazone RS5444 Saroglitazar Sipoglitazar Sodelglitazar Telmisartan Tesaglitazar Troglitazone SPPARMsTooltip Selective PPARγ modulator: BADGE EPI-001 INT-131 MK-0533 S26948 Antagonists: FH-535 GW-9662 SR-202 T-0070907 Unknown: SR-1664
Non-selective	Agonists: Ciprofibrate Clinofibrate Clofibride Englitazone Etofibrate Farglitazar Netoglitazone Ronifibrate Rivoglitazone Simfibrate
See also Receptor/signaling modulators

Clinical data

Pregnancy category	N/A
ATC code	none
Legal status
Legal status	Development discontinued
Identifiers
IUPAC name N-(o-Benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
CAS Number	196808-45-4^Y
PubChem CID	170364
IUPHAR/BPS	2672
ChemSpider	148961^Y
UNII	3433GY7132
KEGG	D04132
ChEMBL	ChEMBL107367^Y
CompTox Dashboard (EPA)	DTXSID1047310
Chemical and physical data
Formula	C₃₄H₃₀N₂O₅
Molar mass	546.623 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5
InChI InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1^N Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N^N
^NY (what is this?) (verify)

Farglitazar

References

Navigation menu

Search